Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
The increasing global prevalence of obesity and type 2 diabetes (T2D) has prompted significant advancements in pharmacological treatments, with glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists representing key innovations. Semaglutide, a GLP-1 receptor agonist, and tirzepatide, a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2024-12-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/56425 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850114287537750016 |
|---|---|
| author | Laura Opalska Adrianna Muciek Martyna Mocarska Anna Orłowska Katarzyna Strakowska Anna Maryńczak Jan Mencel Nicole Nitschke |
| author_facet | Laura Opalska Adrianna Muciek Martyna Mocarska Anna Orłowska Katarzyna Strakowska Anna Maryńczak Jan Mencel Nicole Nitschke |
| author_sort | Laura Opalska |
| collection | DOAJ |
| description |
The increasing global prevalence of obesity and type 2 diabetes (T2D) has prompted significant advancements in pharmacological treatments, with glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists representing key innovations. Semaglutide, a GLP-1 receptor agonist, and tirzepatide, a novel dual agonist targeting both GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors, have shown remarkable efficacy in improving glycemic control and promoting weight loss.
This review synthesizes the latest clinical evidence on the efficacy and safety of semaglutide and tirzepatide in the management of obesity and T2D, highlighting the findings from recent pivotal trials. In patients with T2D, semaglutide has consistently demonstrated superior glycemic control and weight loss compared to traditional therapies, as evidenced by the SUSTAIN trials [1]. Similarly, tirzepatide has emerged as a more efficacious option, with the SURPASS trials demonstrating greater reductions in HbA1c and more substantial weight loss compared to semaglutide. This positions tirzepatide as a potential first-line therapy for T2D.[2].
Both therapies have shown a favorable safety profile, with gastrointestinal side effects being the most common, and cardiovascular benefits observed in both drug classes. Given their dual mechanism of action, tirzepatide has shown unique potential in addressing both glycemic control and obesity, with emerging evidence supporting its use in non-diabetic patients with obesity [3].This review highlights the potential of these agents to revolutionise the management of obesity and T2D, with tirzepatide emerging as a promising next-generation treatment for metabolic diseases.
|
| format | Article |
| id | doaj-art-976e1859cbb64ba7bec8abf417d9244c |
| institution | OA Journals |
| issn | 2450-3118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-976e1859cbb64ba7bec8abf417d9244c2025-08-20T02:36:54ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182024-12-013510.12775/QS.2024.35.56425Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 DiabetesLaura Opalska0https://orcid.org/0009-0007-3122-3484Adrianna Muciek1https://orcid.org/0009-0002-5678-3780Martyna Mocarska2https://orcid.org/0009-0007-4249-9857Anna Orłowska3https://orcid.org/0009-0000-6028-3004Katarzyna Strakowska4https://orcid.org/0009-0006-6202-2055Anna Maryńczak5https://orcid.org/0000-0001-6187-0921Jan Mencel6https://orcid.org/0009-0006-0877-2242Nicole Nitschke7https://orcid.org/0009-0003-9817-7903The University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PLThe University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PLGabriel Narutowicz Municipal Specialist Hospital, Prądnicka 35 Street, 31-202 Kraków: Cracow, Malopolska, PLThe University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PLThe Ludwik Rydygier Memorial Specialized Hospital, Osiedle Złotej Jesieni 1, 31-820 Krakow: Cracow, Malopolska, PLClinical Provincial Hospital No. 2 them. Saint Jadwiga the Queen in Rzeszów, Lwowska 60 -Street, 35-301 Rzeszów, Subcarpathia, PLIndependent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Krakow, Kronikarza Galla 25 Street, 30-053 Krakow: Cracow, Malopolska, PLThe University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PL The increasing global prevalence of obesity and type 2 diabetes (T2D) has prompted significant advancements in pharmacological treatments, with glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists representing key innovations. Semaglutide, a GLP-1 receptor agonist, and tirzepatide, a novel dual agonist targeting both GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors, have shown remarkable efficacy in improving glycemic control and promoting weight loss. This review synthesizes the latest clinical evidence on the efficacy and safety of semaglutide and tirzepatide in the management of obesity and T2D, highlighting the findings from recent pivotal trials. In patients with T2D, semaglutide has consistently demonstrated superior glycemic control and weight loss compared to traditional therapies, as evidenced by the SUSTAIN trials [1]. Similarly, tirzepatide has emerged as a more efficacious option, with the SURPASS trials demonstrating greater reductions in HbA1c and more substantial weight loss compared to semaglutide. This positions tirzepatide as a potential first-line therapy for T2D.[2]. Both therapies have shown a favorable safety profile, with gastrointestinal side effects being the most common, and cardiovascular benefits observed in both drug classes. Given their dual mechanism of action, tirzepatide has shown unique potential in addressing both glycemic control and obesity, with emerging evidence supporting its use in non-diabetic patients with obesity [3].This review highlights the potential of these agents to revolutionise the management of obesity and T2D, with tirzepatide emerging as a promising next-generation treatment for metabolic diseases. https://apcz.umk.pl/QS/article/view/56425Semaglutide, tirzepatide, obesity, type 2 diabetes |
| spellingShingle | Laura Opalska Adrianna Muciek Martyna Mocarska Anna Orłowska Katarzyna Strakowska Anna Maryńczak Jan Mencel Nicole Nitschke Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes Quality in Sport Semaglutide, tirzepatide, obesity, type 2 diabetes |
| title | Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes |
| title_full | Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes |
| title_fullStr | Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes |
| title_full_unstemmed | Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes |
| title_short | Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes |
| title_sort | insights into the efficacy of glp 1 agonists and dual agonists semaglutide and tirzepatide in obesity and type 2 diabetes |
| topic | Semaglutide, tirzepatide, obesity, type 2 diabetes |
| url | https://apcz.umk.pl/QS/article/view/56425 |
| work_keys_str_mv | AT lauraopalska insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT adriannamuciek insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT martynamocarska insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT annaorłowska insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT katarzynastrakowska insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT annamarynczak insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT janmencel insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes AT nicolenitschke insightsintotheefficacyofglp1agonistsanddualagonistssemaglutideandtirzepatideinobesityandtype2diabetes |